TWI889889B - 用於降低異源多肽末端異質性的信號肽 - Google Patents

用於降低異源多肽末端異質性的信號肽

Info

Publication number
TWI889889B
TWI889889B TW110131910A TW110131910A TWI889889B TW I889889 B TWI889889 B TW I889889B TW 110131910 A TW110131910 A TW 110131910A TW 110131910 A TW110131910 A TW 110131910A TW I889889 B TWI889889 B TW I889889B
Authority
TW
Taiwan
Prior art keywords
antibody
seq
signal peptide
light chain
amino acid
Prior art date
Application number
TW110131910A
Other languages
English (en)
Chinese (zh)
Other versions
TW202227482A (zh
Inventor
周松濤
劉洵
Original Assignee
大陸商江蘇恆瑞醫藥股份有限公司
大陸商上海恆瑞醫藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商江蘇恆瑞醫藥股份有限公司, 大陸商上海恆瑞醫藥有限公司 filed Critical 大陸商江蘇恆瑞醫藥股份有限公司
Publication of TW202227482A publication Critical patent/TW202227482A/zh
Application granted granted Critical
Publication of TWI889889B publication Critical patent/TWI889889B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW110131910A 2020-08-28 2021-08-27 用於降低異源多肽末端異質性的信號肽 TWI889889B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010882873 2020-08-28
CN202010882873.5 2020-08-28
CN202110958128 2021-08-20
CN202110958128.9 2021-08-20

Publications (2)

Publication Number Publication Date
TW202227482A TW202227482A (zh) 2022-07-16
TWI889889B true TWI889889B (zh) 2025-07-11

Family

ID=80352714

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110131910A TWI889889B (zh) 2020-08-28 2021-08-27 用於降低異源多肽末端異質性的信號肽

Country Status (7)

Country Link
US (1) US20230312725A1 (https=)
EP (1) EP4206222A4 (https=)
JP (1) JP7817241B2 (https=)
CN (1) CN116234814A (https=)
CA (1) CA3191184A1 (https=)
TW (1) TWI889889B (https=)
WO (1) WO2022042673A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101460520A (zh) * 2006-06-02 2009-06-17 Aveo制药公司 肝细胞生长因子(hgf)的结合蛋白质
US20150225482A1 (en) * 2012-10-12 2015-08-13 Agency For Science, Technology And Research Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2182498A1 (en) * 1994-02-01 1995-08-10 William J. Larochelle Fusion proteins that include antibody and nonantibody portions
IL140110A0 (en) * 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
AU2003237332A1 (en) * 2002-06-03 2003-12-19 Centocor, Inc. Anti-relp fusion antibodies, compositions, methods and uses
AR047440A1 (es) * 2004-01-21 2006-01-18 Novozymes As Produccion de un anticuerpo monoclonal en un hongo heterocarion o una celula huesped fungal
CN101375161A (zh) * 2006-01-27 2009-02-25 默克公司 靶定金黄色葡萄球菌ORF0657n的抗原结合蛋白
AR061171A1 (es) 2006-06-02 2008-08-06 Aveo Pharmaceuticals Inc Proteinas de union al factor de crecimiento de hepatocitos (fch)
AU2008318320B2 (en) 2007-11-02 2014-11-27 The Johns Hopkins University Multitype HPV peptide compositions and methods for treatment or prevention of human papillomavirus infection
WO2016165762A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
MX2021011489A (es) * 2019-04-01 2021-10-22 Jiangsu Hengrui Medicine Co Anticuerpo anti-claudina 18.2 y utilizacion del mismo.
CN114341184B (zh) 2020-02-10 2023-04-04 北京拓界生物医药科技有限公司 抗FcRn抗体、其抗原结合片段及其医药用途
CN113484526B (zh) * 2021-08-11 2024-08-23 上海迈晋生物医药科技有限公司 一种抗FcRn抗体或其抗原结合片段生物学活性的检测方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101460520A (zh) * 2006-06-02 2009-06-17 Aveo制药公司 肝细胞生长因子(hgf)的结合蛋白质
US20150225482A1 (en) * 2012-10-12 2015-08-13 Agency For Science, Technology And Research Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics

Also Published As

Publication number Publication date
TW202227482A (zh) 2022-07-16
US20230312725A1 (en) 2023-10-05
WO2022042673A1 (zh) 2022-03-03
EP4206222A1 (en) 2023-07-05
CN116234814A (zh) 2023-06-06
EP4206222A4 (en) 2024-04-10
CA3191184A1 (en) 2022-03-03
JP2023539581A (ja) 2023-09-15
JP7817241B2 (ja) 2026-02-18

Similar Documents

Publication Publication Date Title
US11149094B2 (en) Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
TWI798179B (zh) 多特異性抗體之純化
KR20140082783A (ko) 이중특이적 항체의 개선된 어셈블리
TWI874341B (zh) 產生異二聚體抗體之方法
TWI889889B (zh) 用於降低異源多肽末端異質性的信號肽
AU2020268399B2 (en) Methods of making antibodies
US20230220114A1 (en) Purification of multispecific antibodies